Steward Partners Investment Advisory LLC Has $32,000 Stake in Exact Sciences Co. (NASDAQ:EXAS)

Steward Partners Investment Advisory LLC decreased its stake in Exact Sciences Co. (NASDAQ:EXASGet Rating) by 87.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 462 shares of the medical research company’s stock after selling 3,164 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Exact Sciences were worth $32,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in EXAS. FSB Premier Wealth Management Inc. acquired a new position in Exact Sciences in the fourth quarter valued at about $36,000. Masso Torrence Wealth Management Inc. bought a new stake in shares of Exact Sciences in the fourth quarter worth about $37,000. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Exact Sciences in the fourth quarter worth about $37,000. HM Payson & Co. increased its holdings in shares of Exact Sciences by 118.6% in the fourth quarter. HM Payson & Co. now owns 481 shares of the medical research company’s stock worth $37,000 after acquiring an additional 261 shares in the last quarter. Finally, Capital Advisory Group Advisory Services LLC bought a new stake in shares of Exact Sciences in the first quarter worth about $37,000. Institutional investors and hedge funds own 94.45% of the company’s stock.

Insider Activity

In other news, Director Katherine S. Zanotti sold 4,608 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total value of $208,005.12. Following the completion of the sale, the director now directly owns 60,318 shares of the company’s stock, valued at $2,722,754.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Katherine S. Zanotti sold 1,086 shares of Exact Sciences stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total transaction of $43,581.18. Following the completion of the sale, the director now directly owns 60,318 shares of the company’s stock, valued at approximately $2,420,561.34. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Katherine S. Zanotti sold 4,608 shares of Exact Sciences stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total value of $208,005.12. Following the completion of the transaction, the director now directly owns 60,318 shares of the company’s stock, valued at $2,722,754.52. The disclosure for this sale can be found here. Insiders sold a total of 5,701 shares of company stock valued at $251,872 over the last three months. Insiders own 1.40% of the company’s stock.

Exact Sciences Stock Performance

EXAS opened at $47.05 on Friday. Exact Sciences Co. has a 12-month low of $35.34 and a 12-month high of $108.99. The stock has a market cap of $8.28 billion, a price-to-earnings ratio of -11.12 and a beta of 1.32. The business has a 50 day moving average of $44.58 and a 200-day moving average of $59.00. The company has a quick ratio of 2.29, a current ratio of 2.48 and a debt-to-equity ratio of 0.70.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Raymond James lowered their price target on Exact Sciences from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Wednesday. Robert W. Baird decreased their price objective on Exact Sciences from $90.00 to $75.00 and set an “outperform” rating for the company in a report on Wednesday. StockNews.com upgraded Exact Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 26th. Cowen decreased their price objective on Exact Sciences from $83.00 to $67.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Piper Sandler began coverage on Exact Sciences in a report on Thursday, June 2nd. They set a “neutral” rating and a $50.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $73.09.

About Exact Sciences

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Featured Articles

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASGet Rating).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Want More Great Investing Ideas?

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.